Long-Term Nonprogression Is a Form of Response to Cardiac Resynchronization Therapy

长期无进展是心脏再同步治疗的一种反应形式

阅读:1

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in selected heart failure patients. A distinct subpopulation (so-called "nonprogressors") of patients shows neither amelioration nor worsening of echocardiographic parameters after CRT implantation. OBJECTIVES: The authors sought to investigate the long-term outcomes and prognosis of a distinct subpopulation of heart failure patients termed "nonprogressors," after CRT implantation. METHODS: Retrospective single-center cohort analysis of 391 patients after CRT implantation. Based on echocardiography, patients were categorized into "super-responders" (Δ left ventricular ejection fraction [LVEF] >15% compared to baseline), "responders" (ΔLVEF >5% compared to baseline), "nonprogressors" (ΔLVEF ±5% compared to baseline), and "progressors" (ΔLVEF <-5% compared to baseline). The primary composite outcome was all-cause death, implantation of a ventricular assist device, or heart transplantation. Statistics included univariable and multivariable Cox proportional hazard regression analysis and Kaplan-Meier survival curves to explore outcome data. RESULTS: A total of 391 patients (23% female, mean age 65 years, mean baseline LVEF 27%) were included. Postimplantation echocardiograms were performed after a mean of 37 months after CRT implantation. A total of 134 patients (34%) were nonprogressors. After a mean follow-up of another 57 months, progressors were significantly more likely to reach the composite endpoint of death, ventricular assist device implantation, or heart transplantation compared to nonprogressors (adjusted HR: 2.26 [95% CI: 1.35-3.78]; P = 0.002). Patients with positive echocardiographic response and super-response fared significantly better compared to nonprogressors. CONCLUSIONS: Nonprogressors form a relevant, to date poorly characterized group of CRT patients, whose long-term survival is significantly better compared to progressors or negative responders.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。